Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy Stent in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Revascularization Followed by 1-Month Dual Antiplatelet Therapy
Phase of Trial: Phase IV
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Antiplatelets; Aspirin
- Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Ischaemia
- Focus Adverse reactions
- Acronyms POEM
- 06 Aug 2019 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 06 Aug 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
- 08 Aug 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.